D C Stump - Concepedia

Author

D C Stump

Also Known As

D C Stump, D Stump, D. C. Stump, D. STUMP, D. Stump, D.C. Stump, David C Stump, David C. Stump, David Stump, David C. Stump

Publications

Citations

H-Index

Concepts

All Affiliations

University of Vermont University of Michigan White River Junction VA Medical Center KU Leuven University of New Mexico

About

D C Stump is an author at University of Vermont specializing in medicine, thrombosis, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	35	3.1K
2	Health Sciences	3	3	309
3	Engineering	2	2	50
4	Law	1	1	36
5	Management	1	1	14

D C Stump

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Eric J. Topol, Barry S. George, Dean J. Kereiakes, Circulation Bleeding ComplicationsCoronary Artery DiseaseAcute Myocardial InfarctionThrombosisVenous Thrombosis	1989	275
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Eric J. Topol, Robert M. Califf, Barry S. George, Circulation PharmacotherapyCoronary Artery DiseaseAcute Myocardial InfarctionThrombosisCombined Infusion	1988	199
Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII D C Stump, R. G. Strauss, R.A. Henriksen, Transfusion SurgeryThrombosisHematologyVascular SurgerySepsis	1985	196
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris Herman K. Gold, F Torres, Harry D. Garabedian, Journal of the American College of Cardiology ThrombosisCardiovascular DiseaseUnstable AnginaHematologySpecific Thrombin Inhibitor	1993	180
Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction Robert M. Califf, Eric J. Topol, Barry S. George, The American Journal of Medicine ThrombosisCardiovascular DiseaseMedicineFibrinolysisAnticoagulant	1988	160
Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis Samuel Z. Goldhaber, Michael F. Meyerovitz, Eugene Braunwald, The American Journal of Medicine ThrombosisVenous DiseaseVenous ThrombosisCardiovascular DiseaseControlled Trial	1990	154
A Controlled Trial of Prophylactic Granulocyte Transfusions during Initial Induction Chemotherapy for Acute Myelogenous Leukemia Ronald G. Strauss, John E. Connett, Robert Peter Gale, New England Journal of Medicine ImmunologyImmunotherapyAcute Myelogenous LeukemiaMyeloid NeoplasiaHematological Malignancy	1981	151
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. Robert M. Califf, Eric J. Topol, Barry S. George, Circulation Percutaneous Coronary InterventionThrombosisResidual StenosisCardiovascular DiseaseCoronary Artery Disease	1988	143
Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. Mary J. Heeb, Francisco España, Margarethe Geiger, Journal of Biological Chemistry Immunocytochemical TechniqueImmunologyPlasminogen Activator Inhibitor-3ImmunotherapyPurified Plasma	1987	136
Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. D C Stump, M Thienpont, Désiré Collen Journal of Biological Chemistry	1986	123

Page 1